Clinical Study

Testing The Effect Of Adding Abiraterone Acetate And Enzalutamide To Metastatic Hormone Refractory Prostate Cancer, When Compared To Enzalutamide Alone

Posted Date: Aug 17, 2017

  • Investigator: Nilesh Patil
  • Co-Investigator: Shelby Whitis
  • Specialties: Hematology/Oncology, Oncology, Cancer
  • Type of Study: Drug

The purpose of this study is to compare the effects, good and/or bad, of abiraterone, prednisone and enzalutamide with enzalutamide alone on patients and their cancer to find out which is better. Doctors are uncertain about which way is the best way to treat castration resistant prostate cancer (CRPC). In previous studies, enzalutamide appeared to e at least as active as abiraterone in patients with CRPC who have received prior chemotherapy and it may be at least as active in patients who have not received chemotherapy.


To Be Eligible To Participate, Patients Must Have Prostate Cancer That Has Spread And Has Not Responded To Hormonal Therapy.


Abiraterone, Metastatic Prostate Cancer, Enzalutamide, Cancer, A031201

For More Information:

Uc Cancer Institute

  • Search Clinical Studies

  • Research in the News

    Enhanced Recovery Program for Colorectal Surgery Patients Reduces Costs

    A standardized protocol for managing patients for the duration of colorectaloperations not only improved clinical outcomes, but also it significantlyreduced hospital costs.